488 related articles for article (PubMed ID: 29340881)
41. Serum DNA integrity index as a potential molecular biomarker in endometrial cancer.
Vizza E; Corrado G; De Angeli M; Carosi M; Mancini E; Baiocco E; Chiofalo B; Patrizi L; Zampa A; Piaggio G; Cicchillitti L
J Exp Clin Cancer Res; 2018 Jan; 37(1):16. PubMed ID: 29382392
[TBL] [Abstract][Full Text] [Related]
42. Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients.
Hendriks RJ; Dijkstra S; Smit FP; Vandersmissen J; Van de Voorde H; Mulders PFA; van Oort IM; Van Criekinge W; Schalken JA
Prostate; 2018 Apr; 78(5):336-342. PubMed ID: 29330943
[TBL] [Abstract][Full Text] [Related]
43. Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients.
Beije N; Sieuwerts AM; Kraan J; Van NM; Onstenk W; Vitale SR; van der Vlugt-Daane M; Dirix LY; Brouwer A; Hamberg P; de Jongh FE; Jager A; Seynaeve CM; Jansen MPHM; Foekens JA; Martens JWM; Sleijfer S
Mol Oncol; 2018 Jan; 12(1):48-57. PubMed ID: 29063679
[TBL] [Abstract][Full Text] [Related]
44. Cell-free DNA as a biomarker for colorectal cancer: a retrospective analysis in patients before and after surgery.
Zhong Y; Zhou Q; Zhang Y; Zhou S; Zhang G; Jiang C; Zhang Z; Zhang X; Xu J; Jin C; Cao L; Chen L
Cell Mol Biol (Noisy-le-grand); 2020 May; 66(2):135-141. PubMed ID: 32415940
[TBL] [Abstract][Full Text] [Related]
45. Plasma Cell-Free DNA as a Predictive Marker after Radiotherapy for Hepatocellular Carcinoma.
Park S; Lee EJ; Rim CH; Seong J
Yonsei Med J; 2018 Jun; 59(4):470-479. PubMed ID: 29749129
[TBL] [Abstract][Full Text] [Related]
46. Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients.
Viller Tuxen I; Barlebo Ahlborn L; Mau-Soerensen M; Staal Rohrberg K; Cilius Nielsen F; Oestrup O; Westmose Yde C; Richter Vogelius I; Lassen U
Br J Cancer; 2019 Jul; 121(2):125-130. PubMed ID: 31186525
[TBL] [Abstract][Full Text] [Related]
47. Cell-Free DNA Variables including Gene Mutations in CA15-3 Normal Breast Cancer Reflect Prognosis.
Xu J; Chen W; Sun Z; Peng H; Zhou C; Pan S
Dis Markers; 2022; 2022():5470166. PubMed ID: 35251373
[TBL] [Abstract][Full Text] [Related]
48. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.
Jovelet C; Ileana E; Le Deley MC; Motté N; Rosellini S; Romero A; Lefebvre C; Pedrero M; Pata-Merci N; Droin N; Deloger M; Massard C; Hollebecque A; Ferté C; Boichard A; Postel-Vinay S; Ngo-Camus M; De Baere T; Vielh P; Scoazec JY; Vassal G; Eggermont A; André F; Soria JC; Lacroix L
Clin Cancer Res; 2016 Jun; 22(12):2960-8. PubMed ID: 26758560
[TBL] [Abstract][Full Text] [Related]
49. Diagnostic relevance of plasma DNA and DNA integrity for breast cancer.
Stötzer OJ; Lehner J; Fersching-Gierlich D; Nagel D; Holdenrieder S
Tumour Biol; 2014 Feb; 35(2):1183-91. PubMed ID: 24018822
[TBL] [Abstract][Full Text] [Related]
50. Plasma cell-free DNA integrity: a potential biomarker to monitor the response of breast cancer to neoadjuvant chemotherapy.
Wang W; Zhang W; Su L; Sang J; Wang S; Yao Y
Transl Cancer Res; 2019 Aug; 8(4):1531-1539. PubMed ID: 35116896
[TBL] [Abstract][Full Text] [Related]
51. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
Karachaliou N; Mayo-de las Casas C; Queralt C; de Aguirre I; Melloni B; Cardenal F; Garcia-Gomez R; Massuti B; Sánchez JM; Porta R; Ponce-Aix S; Moran T; Carcereny E; Felip E; Bover I; Insa A; Reguart N; Isla D; Vergnenegre A; de Marinis F; Gervais R; Corre R; Paz-Ares L; Morales-Espinosa D; Viteri S; Drozdowskyj A; Jordana-Ariza N; Ramirez-Serrano JL; Molina-Vila MA; Rosell R;
JAMA Oncol; 2015 May; 1(2):149-57. PubMed ID: 26181014
[TBL] [Abstract][Full Text] [Related]
52. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.
Uehiro N; Sato F; Pu F; Tanaka S; Kawashima M; Kawaguchi K; Sugimoto M; Saji S; Toi M
Breast Cancer Res; 2016 Dec; 18(1):129. PubMed ID: 27993161
[TBL] [Abstract][Full Text] [Related]
53. Cell-free DNA concentration in patients with clinical or mammographic suspicion of breast cancer.
Peled M; Agassi R; Czeiger D; Ariad S; Riff R; Rosenthal M; Lazarev I; Novack V; Yarza S; Mizrakli Y; Douvdevani A
Sci Rep; 2020 Sep; 10(1):14601. PubMed ID: 32884019
[TBL] [Abstract][Full Text] [Related]
54. Characterization of the release and biological significance of cell-free DNA from breast cancer cell lines.
Wang W; Kong P; Ma G; Li L; Zhu J; Xia T; Xie H; Zhou W; Wang S
Oncotarget; 2017 Jun; 8(26):43180-43191. PubMed ID: 28574818
[TBL] [Abstract][Full Text] [Related]
55. Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis.
Leng S; Zheng J; Jin Y; Zhang H; Zhu Y; Wu J; Xu Y; Zhang P
Clin Chim Acta; 2018 Feb; 477():160-165. PubMed ID: 29113814
[TBL] [Abstract][Full Text] [Related]
56. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.
Earl J; Garcia-Nieto S; Martinez-Avila JC; Montans J; Sanjuanbenito A; Rodríguez-Garrote M; Lisa E; Mendía E; Lobo E; Malats N; Carrato A; Guillen-Ponce C
BMC Cancer; 2015 Oct; 15():797. PubMed ID: 26498594
[TBL] [Abstract][Full Text] [Related]
57. Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence.
Ueda M; Iguchi T; Masuda T; Nakahara Y; Hirata H; Uchi R; Niida A; Momose K; Sakimura S; Chiba K; Eguchi H; Ito S; Sugimachi K; Yamasaki M; Suzuki Y; Miyano S; Doki Y; Mori M; Mimori K
Oncotarget; 2016 Sep; 7(38):62280-62291. PubMed ID: 27556701
[TBL] [Abstract][Full Text] [Related]
58. Assessment of cell-free DNA (cfDNA) concentrations in the perioperative period can predict risk of recurrence in patients with non-metastatic breast cancer.
Hassan F; Wang JH; Cullinane C; Ita M; Corrigan M; O'Leary DP; Redmond HP
Surg Oncol; 2022 Jun; 42():101753. PubMed ID: 35594723
[TBL] [Abstract][Full Text] [Related]
59. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer.
Mu Z; Wang C; Ye Z; Rossi G; Sun C; Li L; Zhu Z; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2017 Oct; 165(3):733-741. PubMed ID: 28687903
[TBL] [Abstract][Full Text] [Related]
60. The analysis of cell-free DNA concentrations and integrity in serum of initial and treated of lymphoma patients.
Wu J; Tang W; Huang L; Hou N; Wu J; Cheng X; Ma D; Qian P; Shen Q; Guo W; Peng W; Liu Y; Jiang C; Feng J
Clin Biochem; 2019 Jan; 63():59-65. PubMed ID: 30292543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
